UChicago Medicine is the first center to successfully enter the first patient into the CytoSorb Therapy In COVID-19 (CTC) Registry. Congratulations to our research team on this tremendous accomplishment!
Dr. Song, Director of the Acute Mechanical Circulatory Support and Extracorporeal Membrane Oxygenation (MCS/ECMO) program, Surgical Director of the Lung Transplant Program, and Cardiac Surgery Research Ambassadorship Program mentor stated, “The COVID-19 pandemic has had a profound impact on the use of ECMO at the University of Chicago Medicine, and at other institutions. We have been confronted with critically-ill COVID-19 patients suffering rapid decline in pulmonary function requiring ECMO support, with a limited number of proven treatment options. The CytoSorb device can be integrated into ECMO circuits to remove the inflammatory cytokines that can cause a “cytokine storm” and many harmful effects to the patient. The Food and Drug Administration issued an Emergency Use Authorization, allowing us to utilize this therapy for COVID-19 patients with severe disease. In these patients, we have seen potential benefits of the device, enabling us to wean patients from ECMO and mechanical ventilation. Now with the advent of the CytoSorb Therapy In COVID-19 (CTC) Registry, institutions around the country will be collecting de-identified clinical data from these patients, to better understand how CytoSorb therapy may be of benefit in COVID-19. We are happy to be the first center to provide data to the CTC Registry to achieve this important goal.”